Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4

Published 28 Sep 2026, 00:34 UTC. Updated 28 Sep 2026, 06:43 UTC.

Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company’s vice president and head of investor relat

Directly affected

GMAB Genmab A/S
Named in this report.
NDAQ Nasdaq
Named in this report.

Indirectly affected

ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.

Price reaction, T-5 to T+3

Ticker	T-5	T-3	T-1	T0	T+1	T+2	T+3
GMAB	—	—	—	—	—	—	—
NDAQ	—	—	—	—	—	—	—
ACHC	—	—	—	—	—	—	—
ASND	—	—	—	—	—	—	—
ATYR	—	—	—	—	—	—	—
BBIO	—	—	—	—	—	—	—
CRDF	—	—	—	—	—	—	—
DVA	—	—	—	—	—	—	—

Genmab A/S (NASDAQ:GMAB) expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, according to Andrew Carlsen, the company’s…

Source: Nasdaq Markets

How far Acadia Healthcare (ACHC) has moved since 28 Sep 2026

Since the first closing price after “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4,” Acadia Healthcare (ACHC) is +7.70%. The S&P 500 fund (SPY) is +0.29% over the same days, a +7.41% difference versus the market.

ACHC

SPY

Official trades in Acadia Healthcare (ACHC) around 28 Sep 2026

Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 1 days after publication, inside 30 days. The filing is listed beside the story “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4.”

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

How busy Taiwan Strait has been lately

Taiwan Strait has 48 linked stories in the last 7 days and 48 in the last 30 on the page that also carries “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4.” The recent pace is rising.

Taiwan Strait stories

Who is named in “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4”

Companies tied to this story

ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 28 Sep 2026 story “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ASND Ascendis Pharma A/S
For “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 28 Sep 2026 story “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
BBIO BridgeBio Pharma
For “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
CRDF Cardiff Oncology
Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence in the 28 Sep 2026 story “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4.” Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
DVA Davita
In “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

How “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4” reaches Acadia Healthcare (ACHC)

On 28 Sep 2026, “Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4” is the story that connects Acadia Healthcare (ACHC) to Taiwan Strait.

For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

The price range for Acadia Healthcare (ACHC), and the dates in the story

ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.

What the saved facts support for Acadia Healthcare (ACHC)

46 out of 100

“Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.